eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
5/2018
vol. 35
 
Share:
Share:
more
 
 
abstract:
Original paper

Chitinase-3-like protein 1 (YKL-40) is a biomarker of severity of joint involvement in psoriatic arthritis

Joanna Salomon, Łukasz Matusiak, Danuta Nowicka-Suszko, Jacek Szepietowski

Adv Dermatol Allergol 2018; XXXV (5): 485-489
Online publish date: 2018/07/19
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
Psoriasis is an inflammatory disease of a complex pathogenesis and arthritis is one of its most common complications. The biological role of chitinase-3-like protein 1 remains unknown. It is suggested that this protein takes part in processes such as proliferation, inflammation and tissue remodelling.

Aim
To determine whether YKL-40 can be a useful biomarker in psoriatic arthritis.

Material and Methods
The study was performed on 42 patients with psoriatic arthritis: 28 men and 14 women, aged from 24 to 71 years. All patients met the diagnostic criteria (CASPAR) for psoriatic arthritis. The severity of psoriatic arthritis was assessed using 28-joint Disease Activity Score with CRP. The assessment of skin lesions was performed by Psoriasis Area and Severity Index (PASI) and, additionally, the Body Surface Area (BSA) was calculated. Blood samples were taken to measure the serum concentration of YKL-40, as well as C-reactive protein, erythrocyte sedimentation rate, white blood cell count and neutrophil count.

Results
YKL-40 serum levels were significantly higher in patients with psoriatic arthritis, compared to the control group. Moreover, a significant positive correlation between the activity of psoriatic arthritis measured by DAS 28 and serum level of YKL-40 was found. There was a positive correlation between serum YKL-40 and BSA, as well as a distinct trend towards significance between YKL-40 and PASI score.

Conclusions
YKL-40 can be a useful biomarker for both diagnosing and monitoring joint involvement in psoriatic patients.

keywords:

chitinase-3-like protein 1, YKL-40, psoriatic arthritis, inflammation

references:
Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009; 361: 496-509.
Lønnberg AS, Skov L. Co-morbidity in psoriasis: mechanisms and implications for treatment. Expert Rev Clin Immunol 2016; 28: 1-8.
Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am 2015; 41: 545-68.
Gottlieb AB, Mease PJ, Mark Jackson J, et al. Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists’ offices. J Dermatolog Treat 2006; 17: 279-87.
Johansen JS, Jensen BV, Roslind A, et al. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev 2006; 15: 194-202.
Volck B, Johansen JS, Stoltenberg M, et al. Studies on YKL-40 in knee joints of patients with rheumatoid arthritis and osteoarthritis. Involvement of YKL-40 in the joint pathology. Osteoarthritis Cartilage 2001; 9: 203-14.
Prakash M, Bodas M, Prakash D, et al. Diverse pathological implications of YKL-40: answers may lie in ‘outside-in’ signalling. Cell Signal 2013; 25: 1567-73.
Erzin Y, Uzun H, Karatas A, Celik AF. Serum YKL-40 as a marker of disease activity and structure formation in patients with Crohn’s disease. J Gastroenterol Hepatol 2008; 23: e357-62.
Matsumoto T, Tsurumoto T. Serum YKL-40 levels in rheumatoid arthritis: correlations between clinical and laboratory parameters. Clin Exp Rheumatol 2001; 19: 655-60.
Taylor WJ, Helliwell PS, Gladman DD. A validation of current classification criteria for the diagnosis of psoriatic arthritis preliminary results of the CASPAR study. Ann Rheum Dis 2005; 64 (Suppl): 107.
Fransen J, Creemers MC, Van Riel PL. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004; 43: 1252-5.
Johansen JS, Kirwan JR, Price PA, Sharif M. Serum YKL-40 concentrations in patients with early rheumatoid arthritis: relation to joint destruction. Scand J Rheumatol 2001; 30: 297-304.
Peltomaa R, Paimela L, Harvey S, et al. Increased level of YKL-40 in sera from patients with early rheumatoid arthritis: a new marker for disease activity. Rheumatol Int 2001; 20: 192-6.
Guan J, Liu Z, Li F, et al. Increased synovial fluid YKL-40 levels are linked with symptomatic severity in knee osteoarthritis patients. Clin Lab 2015; 61: 991-7.
Väänänen T, Koskinen A, Paukkeri EL, et al. YKL-40 as a novel factor associated with inflammation and catabolic mechanisms in osteoarthritic joints. Mediators Inflamm 2014; 2014: 215140.
Kazakova M, Batalov A, Deneva T, et al. Relationship between sonographic parameters and YKL-40 levels in rheumatoid arthritis. Rheumatol Int 2013; 33: 341-6.
Volck B, Johansen JS, Stoltenberg M, et al. Studies on YKL-40 in knee joints of patients with rheumatoid arthritis and osteoarthritis. Involvement of YKL-40 in the joint pathology. Osteoarthritis Cartilage 2001; 9: 203-14.
Bernardi D, Podswiadek M, Zaninotto M, et al. YKL-40 as a marker of joint involvement in inflammatory bowel disease. Clin Chem 2003; 49: 1685-8.
Jensen P, Wiell C, Milting K, et al. Plasma YKL-40: a potential biomarker for psoriatic arthritis? J Eur Acad Dermatol Venereol 2013; 27: 815-9.
Ahmed SF, Attia EA, Saad AA, et al. Serum YKL-40 in psoriasis with and without arthritis; correlation with disease activity and high-resolution power Doppler ultrasonographic joint findings. J Eur Acad Dermatol Venereol 2015; 29: 682-8.
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe